Masterbeef Group (MB) Stock News

Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, as an independent board director, bringing over 25 years of clinical development and regulatory expertise from companies including MyoKardia, Genentech/Roche, Alumis, and Abivax. Zhang will support Aardvark's regulatory strategy for ARD-101, its lead candidate for Prader-Willi Syndrome treatment, at a critical juncture following an FDA clinical hold.

SoFi Technologies launched small business loans in Q2 2026, targeting underserved entrepreneurs with fast funding and competitive pricing. The company is using a capital-light approach through its Loan Platform Business, with $3 billion in capacity from Basepoint Capital and additional partnerships. Total originations reached a record $14.8 billion in Q2, up 69% year-over-year, with potential for future balance sheet retention of SMB loans.

Home BancShares is expected to report Q3 2026 earnings on October 14, with consensus estimates of $0.64 EPS (up 4.9% YoY) and $293 million in revenues (up 5.5% YoY). The stock has a Zacks Rank #2 (Buy) with a positive Earnings ESP of +0.79%, suggesting a likely earnings beat. The company has beaten consensus estimates in 2 of the last 4 quarters.

Bumble Inc. (BMBL) closed at $2.51, down 1.57% and underperforming the S&P 500. The stock has declined 12.07% over the prior period while the tech sector gained 6.31%. Upcoming earnings are projected at $0.24 per share, representing a 31.43% year-over-year decline, with revenue expected at $210.25 million, down 14.59%. Despite weak near-term performance, the company holds a Zacks Rank #2 (Buy) rating.

Kyntra Bio announced the appointment of Andrew E. Singer, an experienced biotechnology finance executive with 25+ years in investment banking and corporate strategy, to its Board of Directors as an independent director and Audit Committee member effective October 1, 2026. Simultaneously, Maykin Ho stepped down after nearly eight years of service. Singer's appointment is expected to strengthen the company's financial position as it advances its rare disease and oncology pipeline.

Hummingbird Bioscience announced that HMBD-001, an anti-HER3 monoclonal antibody developed using its AI Molecular Medicine platform, has advanced into Phase II clinical trials for advanced squamous cell cancers in combination with cetuximab. The first patient has been dosed in the HMBD-001-103 study, with recommended doses identified based on safety, tolerability, and preliminary efficacy data. The advancement demonstrates the company's AI-first approach to drug discovery and development.

Law firm Bernstein Liebhard announced an investigation into potential breaches of fiduciary duty by directors and officers of Embecta Corp. The firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. Current shareholders who purchased shares before November 25, 2025 are encouraged to contact the firm regarding their legal rights.

Bumble Inc. (BMBL) closed at $2.96, down 1.33% while the broader market gained. The company is expected to report lower earnings and revenue compared to the prior year, with EPS projected at $0.24 (down 31.43%) and quarterly revenue at $210.25 million (down 14.59%). The stock holds a Zacks Rank of #3 (Hold), with consensus EPS estimates declining 112.82% over the past month.

Bumble Inc. (BMBL) outperformed the broader market on September 10, 2026, gaining 1.71% while the S&P 500 declined 0.59%. However, the company faces significant headwinds with consensus EPS projections down 31.43% for the upcoming quarter and revenue expected to decline 14.67% year-over-year. The stock holds a Zacks Rank of #3 (Hold), with analyst estimates revised 112.82% lower over the past 30 days.

Ambiq Micro reported strong Q2 2026 earnings with narrower losses, 89.7% revenue growth, and expanding margins driven by accelerating edge AI demand. Despite solid fundamentals and upward estimate revisions, the stock has declined 2.8% since the earnings report. The company guides for continued sequential growth in Q3 and expects second-half 2026 revenues to more than double year-over-year, earning a Zacks Rank #2 (Buy) rating.

Ambarella reported Q3 2026 earnings of $0.18 per share, beating consensus estimates of $0.16, with revenues of $108.13 million slightly exceeding expectations. However, the stock has underperformed the S&P 500 by 5.2% year-to-date and carries a Zacks Rank #3 (Hold) rating. Meanwhile, Descartes Systems is expected to report earnings of $0.57 per share with revenues of $199.04 million when it releases results on September 10.

In a comparison of two Aerospace-Defense stocks, Embraer (EMBJ) and RTX are both rated as Zacks Rank #2 (Buy) with positive earnings outlooks. However, based on valuation metrics, Embraer emerges as the superior value option, featuring a lower forward P/E ratio of 23.62 versus RTX's 27.82, a better PEG ratio of 1.59 compared to 2.59, and a lower P/B ratio of 3.41 versus 3.97. Embraer received a Value grade of B while RTX received a C.

Williams Companies reported Q2 2026 earnings that missed estimates with adjusted EPS of 50 cents versus 52 cents expected, though revenues increased 9.8% year-over-year. The company raised 2026 guidance and announced a $5.5 billion acquisition of Momentum Midstream to expand its natural gas infrastructure. Despite a 5.2% stock gain since earnings, analyst estimates have trended downward, and the stock received a Zacks Rank #3 (Hold) rating with an F VGM Score.

Canada's Drug Agency (CDA-AMC) has issued a final positive recommendation supporting public reimbursement of LEQEMBI (lecanemab) for patients with mild cognitive impairment or mild dementia due to early Alzheimer's disease. The recommendation follows reconsideration and will proceed to negotiations through the pan-Canadian Pharmaceutical Alliance, with individual reimbursement decisions to follow from provincial and territorial drug plans.

UMB Financial's CFO Shankar Ram sold 2,000 shares worth $303,220 on August 17, 2026, reducing his direct holdings by 6%. Despite the sale, Ram maintains significant ownership with 30,389 direct shares and 1,702 indirect shares valued at $4.8 million. The sale appears to be profit-taking as UMB Financial stock has surged 24.7% in 2026, outperforming the S&P 500's 12.1% gain. The company reported strong Q2 earnings with net income up 26.2% year-over-year, and analysts remain bullish with 81% buy ratings and a median price target of $166.50.

Schall, Brown & Schwartz LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged violations of securities laws. The lawsuit claims the company made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to disclose known market headwinds in the pen needle sector. The class period runs from November 25, 2025 to May 4, 2026, with a deadline of August 17, 2026 for investors to participate.

Callan JMB Inc. successfully completed emergency preparedness support for the City of Chicago during the 2026 Lollapalooza weekend, which attracted approximately 460,000 attendees. The engagement continues the company's longstanding partnership with Chicago dating back to 2009, providing logistics, medical supply management, and emergency response capabilities during major public events.

Klépierre, Europe's leading shopping center operator, has raised its full-year 2026 guidance with EBITDA expected to reach a minimum of €1,150 million and improved net current cash flow per share. The company demonstrated strong execution in a dynamic retail market, driving organic growth across its portfolio of over 720 million annual visitors.

Valeo SE has announced the exercise of its make-whole redemption option for €750 million in 5.375% Sustainability Linked Bonds due May 28, 2027. The early redemption is scheduled for August 24, 2026, with the redemption amount to be calculated and published by August 18, 2026. The bonds will be delisted from Euronext following redemption.

Hagens Berman is investigating Embecta Corp. (NASDAQ: EMBC) for allegedly misleading investors about the stability of its insulin pen needle business. The company claimed its pen needle portfolio was 'stable' and 'resilient' while experiencing significant competitive share loss and market volume softness. On May 5, 2026, Embecta revealed massive revenue declines, slashed full-year 2026 adjusted EPS guidance by 43%, and cut its quarterly dividend by 93%, causing the stock to plummet 57.8% in a single trading day. Investors with substantial losses during the class period (Nov. 25, 2025 – May 4, 2026) are encouraged to participate in the lawsuit with a lead plaintiff deadline of August 17, 2026.

Class action lawsuits have been filed against four publicly-traded companies alleging securities fraud. Erasca faces allegations regarding misleading preclinical data comparisons; Via Transportation failed to disclose declining ARR and regulatory issues; Embecta misrepresented guidance and segment weakness; and Zillow mischaracterized its Redfin agreement and downplayed antitrust risks. Investors have until mid-August 2026 to file lead plaintiff motions.

VINCI, a French public limited company, disclosed its capital structure as of 31 July 2026, with 587,033,654 total shares and €1,467,584,135.00 in share capital. The company announced the implementation of its share buyback programme through a share purchase agreement signed with an investment partner.

Embecta Corp. (NASDAQ: EMBC) faces a securities class action lawsuit for allegedly misleading investors about fiscal year 2026 performance. The company promised flat-to-down-2% revenue and $2.80-$3.00 EPS but delivered a 17.4% revenue collapse and slashed earnings guidance by nearly half. The stock plummeted 57.8% on May 5, 2026, from $9.25 to $3.90. The lawsuit alleges management knew of U.S. market weakness when reaffirming guidance between November 25, 2025 and February 5, 2026.

Hagens Berman is investigating Embecta Corp. for alleged securities law violations, claiming the company misrepresented the stability of its insulin pen needle business. On May 5, 2026, Embecta revealed significant revenue decline, slashed full-year EPS guidance by 43%, and cut its quarterly dividend by 93%, causing the stock to plummet 57.8% in a single trading day. The class action lawsuit covers the period from November 25, 2025 to May 4, 2026, with a lead plaintiff deadline of August 17, 2026.

Schall, Brown & Schwartz LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged violations of securities laws. The lawsuit claims the company made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to disclose known market headwinds in the pen needle sector. The class period runs from November 25, 2025 to May 4, 2026, with a deadline of August 17, 2026 for shareholders to participate.

Rosen Law Firm is notifying Embecta Corp. investors who purchased stock between November 25, 2025 and May 4, 2026 about a securities class action lawsuit. The lawsuit alleges that Embecta made false and misleading statements regarding its fiscal results and guidance, specifically touting its pen needle business as 'incredibly resolute' before missing expectations and cutting 2026 guidance. Investors with losses exceeding $100,000 are encouraged to join the class action before the August 17, 2026 lead plaintiff deadline.

Hagens Berman is investigating Embecta Corp. for alleged securities law violations, claiming the company misrepresented the stability of its insulin pen needle business. Embecta's stock plummeted 57.8% after revealing significant revenue decline, slashing full-year EPS guidance by 43% and cutting its quarterly dividend by 93%. The class action lawsuit covers the period from November 25, 2025 to May 4, 2026, with a lead plaintiff deadline of August 17, 2026.

Rosen Law Firm is reminding Embecta Corp. investors who purchased stock between November 25, 2025 and May 4, 2026 of an August 17, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Embecta made false and misleading statements about its fiscal results and guidance, particularly regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance.

Shareholder class action lawsuits have been filed against Embecta Corp. and Via Transportation Inc., with allegations of false statements and failure to disclose segment weakness and revenue guidance disruptions. Additionally, Holzer & Holzer, LLC announced an investigation into ADTRAN Holdings Inc. regarding potential federal securities law violations. Investors who suffered losses during the relevant periods are encouraged to contact the law firm.

Embecta Corp. faces a securities fraud class action lawsuit after its stock plummeted 57.8% on May 5, 2026, when the company revealed disappointing Q2 results and admitted to significant market softness in insulin pens and pen needles. Investors allege the company misrepresented the strength of its insulin pen portfolio prior to the announcement. The lead plaintiff deadline is August 17, 2026.